Andere Sprachen BioMarin Pharmaceutical Inc.

Aktien

924801

US09061G1013

BMRN

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 18.04.2024			% 5 Tage	% 1. Jan.
90.07 ^USD	-0.44%		-1.52%	-6.59%

15.04.	Biomarin Pharmaceutical Insider verkaufte Aktien im Wert von $3.645.000, laut einer aktuellen SEC Einreichung	MT
01.04.	Biomarin Pharmaceutical Insider verkaufte Aktien im Wert von $2.173.341, laut einer aktuellen SEC Einreichung	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Biomarin Pharmaceutical Insider Sold Shares Worth $3,645,000, According to a Recent SEC Filing	15.04.
BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET	10.04.
Biomarin Pharmaceutical Insider Sold Shares Worth $2,173,341, According to a Recent SEC Filing	01.04.
New Data to be presented for BioMarin's VOXZOGO in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting	13.03.
BioMarin Pharmaceutical Says Voxzogo Leads to Height Gains in Children With Achondroplasia	12.03.
L'ETF della settimana: scommettere sull'inversione di tendenza delle biotech	09.03.
ETF van de week: inzetten op de ommekeer in de biotech	08.03.
ETF de la semaine : miser sur le retournement des Biotechs	08.03.
Biomarin Pharmaceutical Insider Sold Shares Worth $348,280, According to a Recent SEC Filing	07.03.
BioMarin Pharmaceutical Appoints Cristin Hubbard as Chief Commercial Officer	07.03.
BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer	07.03.
Biomarin Announces Board Changes, Effective May 20, 2024	07.03.
BioMarin Scheduled to Participate in March Investor Conferences	04.03.
BioMarin Scheduled to Participate in March Investor Conferences	01.03.
BioMarin Pharmaceutical Gets DOJ Subpoena for Documents Related to Vimizim, Naglazyme -- Update	26.02.
BioMarin Pharma gets DOJ subpoena on sponsored testing programs for two therapies	26.02.
BioMarin Pharmaceutical Gets DOJ Subpoena for Documents Related to Vimizim, Naglazyme	26.02.
BioMarin Pharma gets DOJ subpoena on certain drug testing programs	26.02.
BioMarin: Q4 Earnings Snapshot	22.02.
BioMarin Pharmaceutical Q4 Adjusted Earnings, Revenue Rise, 2024 Outlook Set -- Shares Decline After Hours	22.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen BioMarin Pharmaceutical Inc.

Aktien

924801

US09061G1013

BMRN

Andere Sprachen

Filter